| |  Online-Ressource |
|---|
| Verfasst von: | DeAngelo, Daniel J. [VerfasserIn]  |
|---|
| | Walker, Alison R. [VerfasserIn] |
|---|
| | Schlenk, Richard Friedrich [VerfasserIn] |
|---|
| | Sierra, Jorge [VerfasserIn] |
|---|
| | Medeiros, Bruno C. [VerfasserIn] |
|---|
| | Ocio, Enrique M. [VerfasserIn] |
|---|
| | Röllig, Christoph [VerfasserIn] |
|---|
| | Strickland, Stephen A. [VerfasserIn] |
|---|
| | Thol, Felicitas [VerfasserIn] |
|---|
| | Valera, Sue-zette [VerfasserIn] |
|---|
| | Dasgupta, Kohinoor [VerfasserIn] |
|---|
| | Berkowitz, Noah [VerfasserIn] |
|---|
| | Stuart, Robert K. [VerfasserIn] |
|---|
| Titel: | Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia |
|---|
| Verf.angabe: | Daniel J. DeAngelo, Alison R. Walker, Richard F. Schlenk, Jorge Sierra, Bruno C. Medeiros, Enrique M. Ocio, Christoph Röllig, Stephen A. Strickland, Felicitas Thol, Sue-zette Valera, Kohinoor Dasgupta, Noah Berkowitz, Robert K. Stuart |
|---|
| E-Jahr: | 2019 |
|---|
| Jahr: | 01 August 2019 |
|---|
| Umfang: | 7 S. |
|---|
| Fussnoten: | Gesehen am 12.02.2020 |
|---|
| Titel Quelle: | Enthalten in: Leukemia research |
|---|
| Ort Quelle: | Amsterdam [u.a.] : Elsevier Science, 1977 |
|---|
| Jahr Quelle: | 2019 |
|---|
| Band/Heft Quelle: | 85(2019) Artikel-Nummer 106197, 7 Seiten |
|---|
| ISSN Quelle: | 1873-5835 |
|---|
| Abstract: | The role of histone deacetylase inhibitors in the treatment of acute myeloid leukemia (AML) is not well characterized. The current study evaluated the safety and efficacy of panobinostat in combination with idarubicin and cytarabine in newly diagnosed patients aged ≤65 years with primary or secondary high-risk AML based on cytogenetic classification. Treatment included fixed dose idarubicin (12mg/m2/d, IV; day 1–3) and cytarabine (100mg/m2/d, continuous IV infusion; day 1–7) and escalating oral doses of panobinostat at 15mg, 20mg, and 25mg, thrice weekly starting at week 2 of a 28-day cycle. Forty-six patients were enrolled (primary AML [n=36], secondary AML [n=10]). The median age was 55 years. The most common all-grade AEs were diarrhea (54.3%), nausea (39.1%), vomiting, and decreased appetite (each, 21.7%), stomatitis (19.6%), and fatigue (17.4%). The overall response rate was 60.9%, 43.5% achieved a complete remission (CR), and 17.4% achieved CR with incomplete count recovery. The event-free survival at 1-year was 78.3%. Panobinostat in combination with idarubicin and cytarabine demonstrated tolerable safety and efficacy in younger patients with high-risk AML. The recommended phase 2 dose of panobinostat in this combination was 20mg. ClinicalTrials.gov registry no: NCT01242774, and European Trial Registry EudraCT no: 2009-016809-42. |
|---|
| DOI: | doi:10.1016/j.leukres.2019.106197 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.1016/j.leukres.2019.106197 |
|---|
| | Verlag: http://www.sciencedirect.com/science/article/pii/S0145212619301420 |
|---|
| | DOI: https://doi.org/10.1016/j.leukres.2019.106197 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | Acute myeloid leukemia |
|---|
| | AML |
|---|
| | Cytarabine |
|---|
| | Idarubicin |
|---|
| | Panobinostat |
|---|
| K10plus-PPN: | 1689862262 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia / DeAngelo, Daniel J. [VerfasserIn]; 01 August 2019 (Online-Ressource)
